Compugen

Company Deals

Gilead Acquires Pre-Clinical IL-18BP Targeting Antibody Candidate from Compugen in $848 Million Deal

Fineline Cube Dec 20, 2023

Gilead (NASDAQ: GILD) has licensed a potential first-in-class IL-18 binding protein (IL-18BP) targeting antibody candidate...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod